Over the past few decades, many novel biotherapeutics seek to enter clinical development in the quest to address unmet medical needs across various disease areas. Despite the potential of these breakthrough molecules, their development often entails extended timelines and the necessity for customized solutions to address the unique needs of each molecule.
In this insightful webinar, we explore innovative strategies and good practices to accelerate the pathway to clinic, increase specific productivity, and enhance product yield. Our experts will delve into comprehensive and integrated drug substance/drug product DNA-to-IND programs designed to expedite development across various modalities, including: